Jefferies raised the firm’s price target on Viridian Therapeutics (VRDN) to $45 from $44 and keeps a Buy rating on the shares. All key events remain on track, says the analyst, who believes “investor focus is squarely on” the Phase 3 topline readout of subQ elegrobart in REVEAL-1 in Q1, REVEAL-2 in Q2, and the PDUFA decision due on June 30 for intravenous veligrotug under priority review.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRDN:
- Viridian Therapeutics reports Q4 EPS ($1.08), consensus ($1.00)
- Strategic Buy on Viridian Therapeutics Ahead of Veligrotug PDUFA and Elegrobart Phase 3 REVEAL‑1 Readout
- Needham biotech analysts hold an analyst/industry conference call
- Viridian Therapeutics price target raised to $44 from $42 at Evercore ISI
- Viridian Therapeutics initiated with a Buy at UBS